Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
16 Years and older
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:completedIn |
December 2022
|
| gptkbp:condition |
gptkb:COVID-19
|
| gptkbp:enrollment |
1200
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT04052568
|
| gptkbp:intervention |
gptkb:Placebo
gptkb:BNT162b2 Parallel Assignment |
| gptkbp:location |
gptkb:Argentina
gptkb:Brazil gptkb:Germany gptkb:South_Africa gptkb:Turkey gptkb:United_States |
| gptkbp:mask |
Double
|
| gptkbp:officialName |
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
|
| gptkbp:purpose |
Treatment
|
| gptkbp:sponsor |
gptkb:Pfizer
|
| gptkbp:startDate |
August 2019
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:COMP360_(psilocybin_therapy)
|
| gptkbp:bfsLayer |
8
|